Phaseline

Targets › SLC47A2

SLC47A2 (Multidrug and toxin extrusion protein 2): drug programs, companies and trials

1 program from 1 company in 3 trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Oncology, Other; next expected readout Oct 2027.

Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Mediates the efflux of cationic compounds, such as the model cations, tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP+), the platinum-based drug oxaliplatin or weak bases that are positively charged at physiological pH, cimetidine, the platinum-based drugs cisplatin and oxaliplatin or the antidiabetic drug metformin. (UniProt, Q86VL8)

Open in Phaseline: the race on SLC47A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BayerBAY 2927088 (Sevabertinib)
MATE1 and MATE2-K transporter inhibitor
ERBB2, SLC47A1, SLC47A2Phase 3Advanced Non-small Cell Lung Cancer, HER2 Mutation; Advanced Solid Tumors; Healthy ParticipantsOct 2027

Conditions

Advanced Non-small Cell Lung Cancer, HER2 Mutation (1) Advanced Solid Tumors (1) Healthy Participants (1)

Modalities

small molecule (1)

Companies

Bayer (1)

Related targets

ERBB2 (1) SLC47A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.